Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: WDR45

Gene summary for WDR45

Gene summary.

Gene information	Species	Human
	Gene symbol	WDR45
	Gene ID	11152
	Gene name	WD repeat domain 45
	Gene Alias	JM5
	Cytomap	Xp11.23
	Gene Type	protein-coding
	GO ID	GO:0000045
	UniProtAcc	A0A024QYX1

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
11152	WDR45	SYSMH3	Human	Oral cavity	OSCC	1.86e-18	6.33e-01	0.2442
11152	WDR45	SYSMH6	Human	Oral cavity	OSCC	5.45e-05	3.96e-01	0.1275
11152	WDR45	P1_cSCC	Human	Skin	cSCC	3.49e-14	6.37e-01	0.0292
11152	WDR45	P2_cSCC	Human	Skin	cSCC	4.35e-06	3.55e-01	-0.024
11152	WDR45	P4_cSCC	Human	Skin	cSCC	2.40e-05	2.49e-01	-0.00290000000000005
11152	WDR45	P10_cSCC	Human	Skin	cSCC	2.58e-10	5.19e-01	0.1017
11152	WDR45	cSCC_p7	Human	Skin	cSCC	8.04e-04	-1.80e-01	-0.2332
11152	WDR45	male-WTA	Human	Thyroid	PTC	4.20e-31	3.01e-01	0.1037
11152	WDR45	PTC01	Human	Thyroid	PTC	1.54e-13	3.51e-01	0.1899
11152	WDR45	PTC04	Human	Thyroid	PTC	7.67e-12	2.42e-01	0.1927
11152	WDR45	PTC05	Human	Thyroid	PTC	7.61e-22	7.77e-01	0.2065
11152	WDR45	PTC06	Human	Thyroid	PTC	4.43e-24	7.28e-01	0.2057
11152	WDR45	PTC07	Human	Thyroid	PTC	5.59e-41	6.44e-01	0.2044
11152	WDR45	ATC09	Human	Thyroid	ATC	1.88e-04	1.36e-01	0.2871
11152	WDR45	ATC11	Human	Thyroid	ATC	1.25e-02	3.66e-01	0.3386
11152	WDR45	ATC12	Human	Thyroid	ATC	1.83e-17	3.17e-01	0.34
11152	WDR45	ATC13	Human	Thyroid	ATC	4.15e-14	2.84e-01	0.34
11152	WDR45	ATC1	Human	Thyroid	ATC	2.31e-04	1.60e-01	0.2878
11152	WDR45	ATC2	Human	Thyroid	ATC	4.67e-04	9.84e-01	0.34
11152	WDR45	ATC3	Human	Thyroid	ATC	2.94e-04	3.17e-01	0.338

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00004226	Breast	Precancer	autophagy of mitochondrion	14/1080	81/18723	2.01e-04	3.16e-03	14
GO:00617266	Breast	Precancer	mitochondrion disassembly	14/1080	81/18723	2.01e-04	3.16e-03	14
GO:00316679	Breast	Precancer	response to nutrient levels	47/1080	474/18723	2.09e-04	3.27e-03	47
GO:00224119	Breast	Precancer	cellular component disassembly	44/1080	443/18723	3.17e-04	4.51e-03	44
GO:00714969	Breast	Precancer	cellular response to external stimulus	33/1080	320/18723	9.01e-04	1.03e-02	33
GO:00316688	Breast	Precancer	cellular response to extracellular stimulus	27/1080	246/18723	1.02e-03	1.13e-02	27
GO:00092677	Breast	Precancer	cellular response to starvation	19/1080	156/18723	1.65e-03	1.67e-02	19
GO:00425947	Breast	Precancer	response to starvation	22/1080	197/18723	2.30e-03	2.15e-02	22
GO:19030085	Breast	Precancer	organelle disassembly	15/1080	114/18723	2.31e-03	2.15e-02	15
GO:00316697	Breast	Precancer	cellular response to nutrient levels	22/1080	215/18723	6.58e-03	4.53e-02	22
GO:003166714	Breast	IDC	response to nutrient levels	62/1434	474/18723	2.33e-05	5.57e-04	62
GO:007149614	Breast	IDC	cellular response to external stimulus	45/1434	320/18723	5.40e-05	1.15e-03	45
GO:003166814	Breast	IDC	cellular response to extracellular stimulus	35/1434	246/18723	2.79e-04	4.26e-03	35
GO:000042212	Breast	IDC	autophagy of mitochondrion	15/1434	81/18723	1.13e-03	1.23e-02	15
GO:006172612	Breast	IDC	mitochondrion disassembly	15/1434	81/18723	1.13e-03	1.23e-02	15
GO:003166914	Breast	IDC	cellular response to nutrient levels	28/1434	215/18723	4.02e-03	3.25e-02	28
GO:190300812	Breast	IDC	organelle disassembly	17/1434	114/18723	5.99e-03	4.31e-02	17
GO:007149623	Breast	DCIS	cellular response to external stimulus	45/1390	320/18723	2.55e-05	5.87e-04	45
GO:003166723	Breast	DCIS	response to nutrient levels	58/1390	474/18723	1.16e-04	2.03e-03	58
GO:003166822	Breast	DCIS	cellular response to extracellular stimulus	35/1390	246/18723	1.54e-04	2.59e-03	35

Page: 1 2 3 4 5 6 7 8 9 10 11

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

WDR45

SNV

Missense_Mutation

novel

c.890N>T

p.Ser297Ile

p.S297I

Q9Y484

protein_coding

deleterious(0)

possibly_damaging(0.841)

TCGA-A8-A0A4-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

WDR45

SNV

Missense_Mutation

rs782703693

c.808N>C

p.Thr270Pro

p.T270P

Q9Y484

protein_coding

tolerated(0.44)

benign(0.042)

TCGA-AO-A0J5-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Other, specify in notesBisphosphonate

zoledronic

WDR45

SNV

Missense_Mutation

c.1022N>G

p.Asp341Gly

p.D341G

Q9Y484

protein_coding

tolerated(0.08)

possibly_damaging(0.841)

TCGA-B6-A0X1-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

WDR45

SNV

Missense_Mutation

rs782703693

c.808A>C

p.Thr270Pro

p.T270P

Q9Y484

protein_coding

tolerated(0.44)

benign(0.042)

TCGA-D8-A1XT-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin+cyclophosphamide

WDR45

insertion

Nonsense_Mutation

novel

c.878_879insATAAAAGGCCCTTAATGGCATTTACGGCTTGAC

p.Asp293delinsGluTerLysAlaLeuAsnGlyIleTyrGlyLeuThr

p.D293delinsE*KALNGIYGLT

Q9Y484

protein_coding

TCGA-AO-A0JB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

WDR45

SNV

Missense_Mutation

rs192312429

c.527N>T

p.Ala176Val

p.A176V

Q9Y484

protein_coding

deleterious(0.05)

benign(0.017)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

WDR45

SNV

Missense_Mutation

rs782395953

c.335G>A

p.Arg112His

p.R112H

Q9Y484

protein_coding

deleterious(0.02)

benign(0.006)

TCGA-FU-A3HZ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

WDR45

SNV

Missense_Mutation

c.1069N>A

p.Asp357Asn

p.D357N

Q9Y484

protein_coding

tolerated(0.08)

possibly_damaging(0.662)

TCGA-IR-A3LA-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

WDR45

SNV

Missense_Mutation

c.930C>G

p.Ile310Met

p.I310M

Q9Y484

protein_coding

deleterious(0.05)

benign(0.169)

TCGA-IR-A3LL-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

WDR45

SNV

Missense_Mutation

c.1078N>A

p.Asp360Asn

p.D360N

Q9Y484

protein_coding

tolerated(0.07)

benign(0.042)

TCGA-JW-A5VL-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1